Registration - Amendment
COVINGTON & BURLING LLP for MERCK & CO, INC
Client
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 6294, the Re-Valuing Anti-Microbial Products Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| WADE ACKERMAN New | Sr. FDA Counsel, US Senate Committee on Health, Education, Labor & Pensions |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.